UPDATE: Teva Pharma (TEVA) Misses Q3 EPS by 4c, Q4 Guidance Comes in Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Teva Pharma (TEVA) PT Lowered to $14 at Susquehanna
November 6, 2017 7:25 AM ESTSusquehanna lowered its price target on Teva Pharma (NYSE: TEVA) to $14.00 (from $20.00) while maintaining a Positive rating.
Analyst Andrew Finkelstein notes Q3 showed further challenges.
... MoreTeva Pharma (TEVA) PT Slashed to $10 at Cantor Fitzgerald
November 2, 2017 1:39 PM EDTCantor Fitzgerald analyst Louise Chen lowered her price target on Teva Pharma (NYSE: TEVA) to $10.00 (from $17.00) while maintaining a Neutral rating following Q3 miss and lower guide.
Chen thinks the company has some meaningful headwinds which need to be addressed before the... More
Teva Pharma (TEVA) Plunges to Fresh Low, Down 16%
November 2, 2017 9:33 AM EDTTeva Pharma (NYSE: TEVA) Plunges to Fresh Low, Down 16%
... More